Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221838 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
A Phase 4 study, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT07221838 is a Phase 4 study that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT07221838, a Phase 4 study, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
Interventions
- DRUG Ravulizumab
- DRUG Prednisone/Prednisolone
- PROCEDURE Oral Corticosteroid Tapering Schedule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2027-08-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221838
The ClinicalTrials.gov registry entry for NCT07221838 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ravulizumab is the first listed.
NCT07221838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221838 about?
NCT07221838 is a clinical study titled "A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab". This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated wi...
What is the current status of trial NCT07221838?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2026-03-04. Estimated completion is 2027-08-27.
What interventions are being tested in trial NCT07221838?
The interventions under investigation include: Ravulizumab (DRUG), Prednisone/Prednisolone (DRUG), Oral Corticosteroid Tapering Schedule (PROCEDURE).
Who is sponsoring clinical trial NCT07221838?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.